Patents by Inventor Luca Andrea Lotta

Luca Andrea Lotta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment Of Liver Disease With Mitochondrial Glycerol-3-Phosphate Acyltransferase (GPAM) Inhibitors
    Publication number: 20220307032
    Abstract: The present disclosure provides methods of treating subjects having liver disease, and methods of identifying subjects having an increased risk of developing liver disease.
    Type: Application
    Filed: February 25, 2022
    Publication date: September 29, 2022
    Inventors: Luca Andrea Lotta, Niek Verweij, Colm O'Dushlaine, Jonathan Marchini, Aris Baras
  • Treatment Of Liver Disease With Ring Finger Protein 213 (RNF213) Inhibitors
    Publication number: 20220307033
    Abstract: The present disclosure provides methods of treating subjects having a liver disease, and methods of identifying subjects having an increased risk of developing a liver disease.
    Type: Application
    Filed: March 1, 2022
    Publication date: September 29, 2022
    Inventors: Luca Andrea Lotta, Niek Verweij, Manuel Allen Revez Ferreira, Aris Baras
  • Treatment of Liver Diseases With Cell Death Inducing DFFA Like Effector B (CIDEB) Inhibitors
    Publication number: 20220282253
    Abstract: The present disclosure provides methods of treating subjects having a liver disease, and methods of identifying subjects having an increased risk of developing liver disease.
    Type: Application
    Filed: March 31, 2022
    Publication date: September 8, 2022
    Inventors: Niek Verweij, Luca Andrea Lotta, Aris Baras, Mary Haas, Jonas Nielsen, Olukayode Sosina, Adam Locke
  • Treatment of Liver Diseases With Cell Death Inducing DFFA Like Effector B (CIDEB) Inhibitors
    Publication number: 20220220474
    Abstract: The present disclosure provides methods of treating subjects having a liver disease, and methods of identifying subjects having an increased risk of developing liver disease.
    Type: Application
    Filed: December 22, 2021
    Publication date: July 14, 2022
    Inventors: Niek Verweij, Luca Andrea Lotta, Aris Baras, Mary Haas, Jonas Nielsen, Olukayode Sosina, Adam Locke
  • Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors
    Publication number: 20220184114
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: December 13, 2021
    Publication date: June 16, 2022
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors
    Patent number: 11359246
    Abstract: The present disclosure provides methods of treating subjects having obesity, methods of identifying subjects having an increased risk of developing obesity, methods of detecting human G-protein coupled receptor 75 variant nucleic acid molecules and variant polypeptides, and GPR75 variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: June 14, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Luca Andrea Lotta, Manuel Allen Revez Ferreira, Aris Baras, Parsa Akbari, Olukayode Sosina
  • Treatment Of Sepsis With PCSK9 And LDLR Modulators
    Publication number: 20220064652
    Abstract: The present disclosure provides methods of treating subjects having sepsis, SIRS, septic shock, and/or MODS, methods of identifying subjects having an increased risk of developing sepsis, SIRS, septic shock, and/or MODS, and methods of detecting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and/or Low Density Lipoprotein Receptor (LDLR) variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: August 25, 2021
    Publication date: March 3, 2022
    Inventors: Julie Horowitz, Luca Andrea Lotta, Manuel Allen Revez Ferreira, Amy Damask, Charles Paulding, Garen Manvelian, Michael Cantor, Aris Baras
  • Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR)
    Publication number: 20220049308
    Abstract: The present disclosure provides methods of treating subjects having obesity and/or increased body mass index (BMI), and methods of identifying subjects having an increased risk of developing obesity and/or BMI.
    Type: Application
    Filed: August 13, 2021
    Publication date: February 17, 2022
    Inventors: Luca Andrea Lotta, Parsa Akbari, Manuel Allen Revez Ferreira, Aris Baras
  • Treatment Of Obesity With G-Protein Coupled Receptor 75 (GPR75) Inhibitors
    Publication number: 20220042101
    Abstract: The present disclosure provides methods of treating subjects having obesity, methods of identifying subjects having an increased risk of developing obesity, methods of detecting human G-protein coupled receptor 75 variant nucleic acid molecules and variant polypeptides, and GPR75 variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: June 21, 2021
    Publication date: February 10, 2022
    Inventors: Luca Andrea Lotta, Manuel Allen Revez Ferreira, Aris Baras, Parsa Akbari, Olukayode Sosina
  • Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) Variants And Uses Thereof
    Publication number: 20210353709
    Abstract: Methods of treating obesity and methods of identifying susceptibility of an obese subject to treatment with an agonist of the leptin-melanocortin signaling pathway are provided herein.
    Type: Application
    Filed: May 3, 2021
    Publication date: November 18, 2021
    Inventors: Luca Andrea Lotta, Manuel Allen Revez Ferreira